Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S.

在其他近期新闻中，Biodexa Pharmaceuticals PLC已任命Precision for Medicine, ...

Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...

In December, the FDA finalized a rule that updates the nutritional requirements a human food item must meet to claim on its packaging that it is “healthy.” That rule was published with an ...

Stephen Stamp, CEO and CFO of Biodexa, commented “The FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity ...

Stephen Stamp, CEO and CFO of Biodexa, commented “The FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity ...

Stephen Stamp, CEO and CFO of Biodexa, commented "The FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity from ...

The chief said the loss of critical employees overseeing the nation’s food supply made his work impossible. Robert F. Kennedy Jr., the nation’s new health secretary, has pledged to gut the ...

Probationary employees across the FDA received notices Saturday evening that their jobs were being eliminated, according to three FDA staffers who spoke to The Associated Press on condition of ...

Dr. Frances O. Kelsey, pictured here in the 1960s, spent most of her career at the FDA overseeing scientific investigations of drugs. It was an application from William S. Merrell, an Ohio ...